Search research articles
Contact Us
Filters
Showing results (21-30 of 63) with videos related to
Page
of 7
Sort By:
Bioanalysis
|
May 1, 2023
Characterization of murine lymphocyte activation and exhaustion markers by a 14-color flow cytometry panel
Daniel C Rose, Annah S Rolig, William L Redmond
Plos One
|
April 13, 2012
Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression
William L Redmond, Todd Triplett, Kevin Floyd, et al.
Journal for Immunotherapy of Cancer
|
March 6, 2015
Professional development session for early career scientists at SITC 2012
Christian M Capitini, William L Redmond, Kimberly A Shafer-Weaver
Advances in Experimental Medicine and Biology
|
January 5, 2020
Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy
Nataliya Prokhnevska, Dana A Emerson, Haydn T Kissick, et al.
Plos One
|
February 17, 2021
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers
Zhaoyu Sun, Richard Nyberg, Yaping Wu, et al.
European Journal of Immunology
|
December 22, 2006
Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses
Carl E Ruby, William L Redmond, Daniel Haley, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 9, 2008
The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen
William L Redmond, Cheng-Hong Wei, Huub T C Kreuwel, et al.
Journal for Immunotherapy of Cancer
|
November 21, 2014
Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells
Michael J McNamara, Melissa J Kasiewicz, Stefanie N Linch, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 21, 2007
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist
William L Redmond, Michael J Gough, Bridget Charbonneau, et al.
Cancer Research
|
July 3, 2008
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor
Michael J Gough, Carl E Ruby, William L Redmond, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 63) with videos related to
Sort By:
Page
of 7
Bioanalysis
|
May 1, 2023
Characterization of murine lymphocyte activation and exhaustion markers by a 14-color flow cytometry panel
Daniel C Rose, Annah S Rolig, William L Redmond
Plos One
|
April 13, 2012
Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression
William L Redmond, Todd Triplett, Kevin Floyd, et al.
Journal for Immunotherapy of Cancer
|
March 6, 2015
Professional development session for early career scientists at SITC 2012
Christian M Capitini, William L Redmond, Kimberly A Shafer-Weaver
Advances in Experimental Medicine and Biology
|
January 5, 2020
Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy
Nataliya Prokhnevska, Dana A Emerson, Haydn T Kissick, et al.
Plos One
|
February 17, 2021
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers
Zhaoyu Sun, Richard Nyberg, Yaping Wu, et al.
European Journal of Immunology
|
December 22, 2006
Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses
Carl E Ruby, William L Redmond, Daniel Haley, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 9, 2008
The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen
William L Redmond, Cheng-Hong Wei, Huub T C Kreuwel, et al.
Journal for Immunotherapy of Cancer
|
November 21, 2014
Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells
Michael J McNamara, Melissa J Kasiewicz, Stefanie N Linch, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 21, 2007
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist
William L Redmond, Michael J Gough, Bridget Charbonneau, et al.
Cancer Research
|
July 3, 2008
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor
Michael J Gough, Carl E Ruby, William L Redmond, et al.
Page
of 7